Stock Report

All about this stock under one free report Last Updated: 01-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Gland Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GLAND | BSE: 543245

₹2,885.80

up-down-arrow ₹-2.20 (-0.08%)

As on 31-Aug-2026IST

Market cap

info icon

₹47,647 Cr

Revenue (TTM)

info icon

₹6,725 Cr

P/E Ratio

info icon

42.2

P/B Ratio

info icon

4.5

Div. Yield

info icon

0.7 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 1.99 23.85 15.86 9.62 5.16
EBIT -7.54 36.33 19.89 23.17 5.48
Net Profit -13.33 35.33 24.36 22.22 6.44
EPS -13.44 35.17 22.72 23.83 5.76
Book Value -- -- 12.70 9.01 11.74
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 31.1721.6219.5918.7515.86
Net Margin info 25.3317.3716.0215.2311.98
Return on equity info 12.2011.3211.5110.567.82
Return on Capital info 16.5715.89--14.9611.97
Return on Assets info 11.379.889.518.706.41
Debt to Equity (x) info ----0.010.020.03

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
--
14.96
11.97
13.63
14.04
Peer Median
--
14.32
12.19
11.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

11.51

Higher than Peers by 3.37

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
11.51
10.56
7.82
9.26
10.34
Peer Median
8.14
11.24
9.26
7.17
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

9.51

Higher than Peers by 3.69

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
9.51
8.70
6.41
7.97
9.40
Peer Median
5.82
6.00
7.65
3.78
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

19.59

Higher than Peers by 10.58

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
19.59
18.75
15.86
17.45
24.22
Peer Median
9.01
21.37
--
12.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

16.02

Higher than Peers by 9.39

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
16.02
15.23
11.98
13.24
20.21
Peer Median
6.63
6.14
5.63
2.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
--
22.56
19.16
19.72
25.60
Peer Median
--
0.00
--
0.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

17.57

Higher than Peers by 2.90

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
17.57
14.50
-0.85
56.29
-17.64
Peer Median
14.67
52.85
--
39.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

33.69

Higher than Peers by 17.14

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
33.69
35.33
-9.86
12.58
-37.28
Peer Median
16.55
213.56
--
20.42
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

24.36

Higher than Peers by 16.86

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
24.36
47.07
-9.57
-1.10
-35.54
Peer Median
7.50
210.06
--
12.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

22.72

Higher than Peers by 5.52

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
22.72
47.07
-9.60
-1.11
-35.70
Peer Median
17.19
202.77
--
33.33
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
--
12.70
4.91
9.62
11.38
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.01

Higher than Peers by 0.01

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
0.01
0.02
0.03
0.04
0.00
Peer Median
0.00
0.24
0.22
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

4.68

Higher than Peers by 2.57

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
4.68
4.68
4.33
4.04
9.46
Peer Median
2.11
2.03
1.99
2.03
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

3.60

Higher than Peers by 2.17

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
3.60
3.60
3.26
2.85
6.80
Peer Median
1.43
5.42
--
1.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

61.70

Higher than Peers by 54.30

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
61.70
45.01
26.30
44.23
142.61
Peer Median
7.40
3.95
4.14
2.98
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

28.12

Higher than Peers by 2.22

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
28.12
29.41
27.00
27.52
24.04
Peer Median
25.91
50.20
--
29.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.57

Lower than Peers by 0.18

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
0.57
0.54
0.52
0.58
0.44
Peer Median
0.75
2.93
--
1.55
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
--
96.72
99.92
78.29
97.99
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
--
97.32
108.54
116.00
157.65
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
--
134.60
138.65
113.80
113.72
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
--
59.43
69.81
80.48
141.92
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

42.21

Higher than Peers by 7.41

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
42.21
27.22
37.55
39.27
26.75
Peer Median
34.80
36.58
44.20
39.23
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

4.48

Higher than Peers by 0.45

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
4.48
2.71
2.87
3.48
2.63
Peer Median
4.04
2.31
2.96
2.56
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.69

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
0.69
1.18
1.13
1.09
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

21.50

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
21.50
12.77
16.15
19.17
13.54
Peer Median
--
13.94
23.15
24.73
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

47,647

Higher than Peers by 47,595

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Gland Pharma
47,647
27,965
26,233
30,338
20,894
Peer Median
52
55
55
58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...